Lead Product(s) : Nimesulide
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nimesulide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 04, 2016
Lead Product(s) : Nimesulide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nimesulide
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Angelini Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Helsinn and Angelini Renew Partnership for AULIN® and MESULID® in Central Europe
Details : Through the agreement, Angelini Pharma will focus on commercializing Mesulid (nimesulide) in Europe. It is indicated for treating patients suffering from acute pain.
Product Name : Mesulid
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 24, 2024
Lead Product(s) : Nimesulide
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Angelini Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Nimesulide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Nimesulide 100 mg Tablets
Details : Nimesulide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 10, 2012
Lead Product(s) : Nimesulide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nimesulide
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Two Therapies for the Treatment of Osteoarticular Inflammation in Dyspeptic Patients
Details : Nimesulide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Inflammation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 22, 2012
Lead Product(s) : Nimesulide
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
